clinical program News
-
New Corporate Identity For Feldan Therapeutics
Feldan Therapeutics is proud to unveil its new corporate identity! This new visual highlights the company's commitment to the therapeutic development of the Feldan Shuttle technology, an innovation developed in-house by Feldan's scientists. The company's initial focus, which was the production and sale of recombinant proteins, was gradually put aside to fully concentrate efforts on the ...
-
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 March 2022 Key highlights from this period include: Strategic appointments to Botanix’s executive leadership team,including Dr Patty Walker as Chief Medical Officer and Mr Howie McKibbon as Chief Commercial Officer Danny Sharp also joins as Non-Executive ...
-
Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS
Curasight A/S (“Curasight” or the “Company”) has today signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform. Curasight has signed and completed an agreement to acquire all outstanding shares in TRT Innovations, ...
By Curasight
-
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects. Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. The Independent Data ...
-
Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden
Our Phase IIa clinical trial evaluating the safety, tolerability and possible efficacy of subcutaneous injections of ILB® in ALS is finalized and has been reported to the Swedish Medical Products Agency. The results indicate that, for the variants of ALS and the given dose investigated in the study, ILB® seems to have beneficial clinical effects without significant side effects. A ...
By TIKOMED AB
-
Positive FDA Guidance For Covid-19 Clinical Program
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to ...
-
CUTISS receives Positive Opinion from the Paediatric Committee of the EMA for denovoSkin™
CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for its proposed Paediatric Investigation Plan (PIP) for ...
By CUTISS AG
-
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three ...
By CervoMed
-
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® (tecovirimat) available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform ...
-
Appointment of Cassandra Harrison to Vice President Clinical Operations and Data Management
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management. Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data ...
-
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma (“Nuance”), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening ...
By Aerogen
-
Curasight expands its strategy and strengthen its position as a theranostic company
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. With reference to the ...
By Curasight
-
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR®
TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological ...
By TIKOMED AB
-
ABK Biomedical Inc. Raises $30M USD in Series B Financing
ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems. ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres™, which are designed for ...
-
Ascelia Pharma’s Food Effect Study with Orviglance successfully completed
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA. ...
-
Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based ...
-
FARAPULSE Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation
FARAPULSE Inc. ("FARAPULSE" or "the Company") today announced that it has received the Conformite Europeene (CE) Mark for its FARAPULSE Pulsed Field Ablation (PFA) system for the treatment of Paroxysmal Atrial Fibrillation (AF). The approval makes FARAPULSE the first company in the world to commercialize a cardiac PFA system and permits marketing of the system across the European Union and other ...
-
Xeltis accelerating clinical trial program
Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the Medtech and Diagnostics Forum organised by the investment bank Canaccord Genuity Capital Markets. Xeltis currently has three restorative devices in ...
By XELTIS BV
-
Axial Therapeutics to Present at the Inaugural Virtual H.C. Wainwright BioConnect Conference
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference 2021. The session will become available for on-demand viewing at 6:00 a.m. ET on ...
-
Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, January 5, 2021 at 8:00 PM EST. About Axial Therapeutics Axial ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you